HC Wainwright Weighs in on Xeris Biopharma Q2 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities research analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Xeris Biopharma in a research note issued on Monday, March 2nd. HC Wainwright analyst B. Folkes expects that the company will earn $0.01 per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.06 EPS, FY2027 earnings at $0.17 EPS, FY2028 earnings at $0.36 EPS, FY2029 earnings at $0.66 EPS and FY2030 earnings at $0.91 EPS.

XERS has been the subject of a number of other reports. Piper Sandler boosted their price target on Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Oppenheimer reissued an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Barclays began coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 price target on the stock. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.08.

Xeris Biopharma Trading Up 2.2%

Shares of Xeris Biopharma stock opened at $6.07 on Wednesday. The business has a 50 day moving average price of $7.16 and a 200 day moving average price of $7.61. The company has a market capitalization of $1.05 billion, a P/E ratio of -606.39 and a beta of 0.61. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.35. Xeris Biopharma has a 1 year low of $3.65 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%.

Institutional Trading of Xeris Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG boosted its position in Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after purchasing an additional 1,554,869 shares during the period. Vanguard Group Inc. raised its position in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd lifted its stake in shares of Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares during the period. Finally, CenterBook Partners LP boosted its position in shares of Xeris Biopharma by 237.7% in the second quarter. CenterBook Partners LP now owns 1,594,229 shares of the company’s stock worth $7,445,000 after buying an additional 1,122,154 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Insider Buying and Selling

In other Xeris Biopharma news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $7.09, for a total transaction of $106,350.00. Following the completion of the sale, the director owned 142,500 shares of the company’s stock, valued at approximately $1,010,325. The trade was a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $7.43, for a total value of $123,835.81. Following the sale, the insider owned 1,308,103 shares of the company’s stock, valued at $9,719,205.29. This represents a 1.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 240,308 shares of company stock worth $1,732,453 over the last 90 days. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Analyst support — HC Wainwright reiterated a “Buy” rating and a $10 price target while publishing multi-year EPS models that show the company returning to positive earnings by FY2026 and rising thereafter; that bullish stance supports investor optimism. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright
• Positive Sentiment: Earnings beat — Xeris reported Q4 2025 adjusted EPS above consensus (roughly $0.0615 vs. $0.03 expected), indicating improving profitability that investors are rewarding. Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
• Positive Sentiment: Bull thesis coverage — A Seeking Alpha piece argues Xeris is undervalued given its drug portfolio upside, which can attract value-oriented and growth investors. Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
• Neutral Sentiment: Profitability vs. legal risk — Coverage highlights that Xeris has achieved new profitability metrics but is simultaneously engaged in patent disputes over Recorlev; this balances upside with legal uncertainty, creating a mixed signal for investors. Xeris Biopharma Balances New Profitability With Recorlev Patent Battles
• Negative Sentiment: Insider sale — Director/insider Beth Hecht sold 16,667 shares at about $6.25 on March 2, modestly reducing her stake; insider selling can raise caution among investors even if the position remains large. SEC Form 4 — Beth Hecht
• Negative Sentiment: Analyst estimate cuts — Although HC Wainwright kept a Buy rating, it trimmed several multi-year EPS forecasts (FY2026–FY2029/FY2030 adjustments), which reduces the magnitude of long-term upside implied by prior models. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.